For couples navigating the uncertain terrain of trying to conceive, the standard home test offers a binary answer. A single line, or a digital smiley face, indicates a surge in luteinizing hormone (LH) and a probable fertile window. It is a snapshot, not a chart. Inito, a healthtech company founded in Bengaluru in 2014, is betting that a more comprehensive picture,quantitative readings of four key reproductive hormones,can provide not just more data, but more clarity and confidence [TechCrunch, Nov 2023]. Its wedge is a small, smartphone-attached reader that uses the phone's own camera as a microscope, a piece of clever hardware engineering that has now cleared the regulatory pathway of the US Food and Drug Administration [Entrepreneur.com, 2026].
The quantitative wedge
Inito's core product is the Inito Fertility Monitor, a direct-to-consumer device that works with proprietary urine test strips. Unlike over-the-counter ovulation predictor kits that typically measure only LH, the Inito system tracks estrogen (E2), LH, progesterone (PdG), and follicle-stimulating hormone (FSH) [TechCrunch, Nov 2023]. The company's technical claim is that by measuring PdG, it can objectively confirm ovulation has occurred, moving beyond prediction to confirmation. The device itself is a reader that attaches to a smartphone. It uses the phone's camera to detect colorimetric changes on the test strip, translating them into lab-like quantitative values for each hormone, which are then displayed and tracked in a companion app [India Science and Technology, Unknown].
This multi-hormone approach is the company's primary differentiator in a crowded market. The clinical rationale is sound: fertility is a symphony of hormones, not a solo act. Tracking only LH can miss the early estrogen rise that signals the opening of the fertile window, and it cannot confirm the progesterone surge that follows ovulation. For users, especially those who have been trying for several cycles without success, this fuller dataset aims to reduce ambiguity. The company claims to have analyzed more than 30 million fertility hormone data points since 2021, building a proprietary corpus that informs its algorithms [HT World, Unknown].
A ten-year path to FDA clearance
Inito's journey to its recent $29 million Series B round, led by Bertelsmann India Investments, has been a long one [HT World, Unknown]. Founded in 2014, the company went through Y Combinator's Winter 2018 batch and raised a $2 million seed round the following year [YourStory, Nov 2019]. A $6 million Series A from Fireside Ventures followed in late 2023 [TechCrunch, Nov 2023]. The decade-long timeline underscores the complexity of developing, validating, and regulating a diagnostic hardware product, even one aimed at the consumer market.
The recent FDA clearance is a significant, if nuanced, milestone. The agency has determined the Inito Fertility Monitor is a Class I exempt device, meaning it does not require a full pre-market approval but has been reviewed for safety and effectiveness for its intended use [Wboy.com, 2026]. This regulatory green light is essential for consumer trust and for sales in the critical US market, where the company now maintains an office in San Francisco alongside its Bengaluru headquarters. It also validates the core imaging technology, which the founders have suggested could be a platform for other home diagnostics, from thyroid function to vitamin levels [YourStory, Nov 2019].
The team and the traction
The company is led by its two technical co-founders, who have built the business around their imaging innovation. CEO Aayush Rai, an IIT Roorkee graduate in electrical engineering, and CTO Varun A Venkatesan, an IIT Madras alumnus in engineering design with prior experience at Siemens, developed the underlying "flat lens" imaging system [Forbes India, Unknown] [TechCrunch, Nov 2023]. Their backgrounds in med-tech and imaging provided a foundation for tackling the precision required for clinical-grade readings at home. The company now employs an estimated 51-200 people, reflecting its shift from pure R&D to commercial scaling [ZoomInfo.com, Unknown].
| Founder | Role | Background |
|---|---|---|
| Aayush Rai | Co-founder & CEO | IIT Roorkee (Electrical Engineering), medical device imaging [Forbes India, Unknown] |
| Varun A Venkatesan | Co-founder & CTO | IIT Madras (Engineering Design), former Siemens engineer [TechCrunch, Nov 2023] |
Traction is primarily measured in user adoption and data volume. Selling directly through its website and marketplaces like Amazon, Inito has built a user base that allows it to cite the 30-million-plus data point figure [HT World, Unknown]. The recent large Series B round indicates investor confidence that this quantitative, multi-hormone approach can capture meaningful market share from the dominant single-hormone kits.
The competitive and clinical landscape
Inito does not have the field to itself. It competes with other advanced at-home fertility monitors like Mira and Proov, as well as established brands like Clearblue. The competitive risks are clear and come from several directions.
- Clinical validation. While the company claims higher accuracy through multi-hormone tracking, these are company-provided claims [TechCrunch, Nov 2023]. Widespread adoption by reproductive endocrinologists or inclusion in clinical guidelines would require independent, peer-reviewed studies demonstrating improved outcomes, such as shorter time-to-pregnancy.
- Consumer behavior. The product asks for a higher engagement level than a simple strip test. Users must consistently test, use the reader and app, and interpret more complex charts. The value proposition must be compelling enough to overcome the friction of a more involved routine.
- Platform expansion. The vision of the device as a platform for other diagnostics is ambitious but unproven. Each new test would require its own clinical validation, regulatory work, and strip chemistry, representing a separate R&D mountain to climb.
Inito's answer to these risks lies in its first-mover advantage in quantitative, multi-hormone tracking with FDA clearance. By building a deep dataset and a loyal user base, it hopes to establish its method as a new standard for the proactive fertility consumer.
The standard of care and the road ahead
The condition Inito addresses is the broad, often stressful experience of trying to conceive. The patient population is vast, encompassing millions of individuals and couples globally who are actively planning a pregnancy. For them, the current standard of care at home remains the single-hormone ovulation predictor kit, a multi-billion dollar market built on a simpler, less informative technology. The clinical standard involves blood draws and ultrasound monitoring at a fertility clinic, which is accurate but expensive, invasive, and inaccessible to many.
Inito's bet is that it can carve out a new middle ground: providing a level of insight approaching the clinical, but in the privacy and convenience of home, at a consumer price point. The next twelve months will be about scaling on the back of its Series B capital and FDA clearance. Key milestones to watch will be user growth in the US, any partnerships with employer benefits programs or telehealth providers, and the first published research stemming from its aggregated dataset. For a company that has spent a decade refining its hardware, the real test is just beginning: whether a richer data stream can fundamentally change the home fertility journey for the better.
Sources
- [TechCrunch, Nov 2023] Inito, a startup that helps women quickly track fertility hormones at home, raises $6M | https://techcrunch.com/2023/11/15/inito-helps-women-quickly-track-fertility-hormones-at-home-raises-6m/
- [HT World, Unknown] Fertility startup Inito raises US$29 million in Series B | https://www.htworld.co.uk/by-region/the-americas/fertility-startup-inito-raises-us29-million-in-series-b-fem26/
- [Entrepreneur.com, 2026] Inito Fertility Monitor clears US FDA pathway | https://www.entrepreneur.com/en-in/news-and-trends/inito-fertility-monitor-clears-us-fda-pathway/492083
- [India Science and Technology, Unknown] Inito | https://www.indiascienceandtechnology.gov.in/hi/technologies/inito
- [YourStory, Nov 2019] y combinator startup medical device inito fertility healthtech | https://yourstory.com/2019/11/y-combinator-startup-medical-device-inito-fertility-healthtech
- [Forbes India, Unknown] getting expertise is a big problem in india initos aayush rai | https://www.forbesindia.com/article/startups/getting-expertise-is-a-big-problem-in-india-initos-aayush-rai/63361/1
- [Wboy.com, 2026] FDA clearance for Inito Fertility Monitor | https://www.wboy.com/business/press-releases/ein-presswire/725661687/inito-fertility-monitor-clears-the-regulatory-pathway-of-the-us-food-and-drug-administration-fda/
- [ZoomInfo.com, Unknown] Inito company profile | https://www.zoominfo.com/c/inito/542926174